Sharon O'Keefe
Sharon O'Keefe's purchase track record
Sharon O'Keefe has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/23/2022 | CVSA | $26K | +61.5% | +101.3% | -2.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Covista receives mixed analyst coverage and rating update. Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.
Transaction History
| CBLL | ▲ Buy | Grant | 16,011 | $0 | 7/28/2026 | View on chart |
| CVSA | ▲ Buy | Grant | 1,445 | $140K | 11/12/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 1,560 | $140K | 11/13/2024 | View on chart |
| CVSA | ▲ Buy | Grant | 2,530 | $140K | 11/8/2023 | View on chart |
| CVSA | ▲ Buy | Grant | 2,930 | $125K | 11/9/2022 | View on chart |
| CVSA | ▲ Buy | Open Market | 1,250 | $26K | 2/23/2022 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 1,178 | $37K | 11/17/2021 | View on chart |
| CVSA | ▲ Buy | Grant | 3,690 | $125K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
CeriBell Gets FDA Clearance for New EEG Analysis Tools
CeriBell Inc. announced that the FDA has granted 510(k) clearance for its quantitative EEG trending and amplitude-integrated EEG analysis features. This regulatory approval allows the company to market these specific diagnostic tools, which may support its clinical utility and product roadmap. The stock is currently trading within its 52-week range, with analyst targets averaging $28.00.
CeriBell Gets FDA Clearance for New EEG Analysis Tools. CeriBell Inc. announced that the FDA has granted 510(k) clearance for its quantitative EEG trending and amplitude-integrated EEG analysis features. This regulatory approval allows the company to market these specific diagnostic tools, which may support its clinical utility and product roadmap. The stock is currently trading within its 52-week range, with analyst targets averaging $28.00.